Literature DB >> 26814202

Oxidative stress and abdominal aortic aneurysm: potential treatment targets.

Theophilus I Emeto1, Joseph V Moxon2, Minnie Au3, Jonathan Golledge4.   

Abstract

Abdominal aortic aneurysm (AAA) is a significant cause of mortality in older adults. A key mechanism implicated in AAA pathogenesis is inflammation and the associated production of reactive oxygen species (ROS) and oxidative stress. These have been suggested to promote degradation of the extracellular matrix (ECM) and vascular smooth muscle apoptosis. Experimental and human association studies suggest that ROS can be favourably modified to limit AAA formation and progression. In the present review, we discuss mechanisms potentially linking ROS to AAA pathogenesis and highlight potential treatment strategies targeting ROS. Currently, none of these strategies has been shown to be effective in clinical practice.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  abdominal aortic aneurysm; animal models; clinical trial; oxidative stress; pharmacotherapy

Mesh:

Substances:

Year:  2016        PMID: 26814202     DOI: 10.1042/CS20150547

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  37 in total

1.  Female Mice With an XY Sex Chromosome Complement Develop Severe Angiotensin II-Induced Abdominal Aortic Aneurysms.

Authors:  Yasir Alsiraj; Sean E Thatcher; Richard Charnigo; Kuey Chen; Eric Blalock; Alan Daugherty; Lisa A Cassis
Journal:  Circulation       Date:  2016-11-04       Impact factor: 29.690

2.  Endothelial Cell Tetrahydrobiopterin Modulates Sensitivity to Ang (Angiotensin) II-Induced Vascular Remodeling, Blood Pressure, and Abdominal Aortic Aneurysm.

Authors:  Surawee Chuaiphichai; Victoria S Rashbrook; Ashley B Hale; Lucy Trelfa; Jyoti Patel; Eileen McNeill; Craig A Lygate; Keith M Channon; Gillian Douglas
Journal:  Hypertension       Date:  2018-05-29       Impact factor: 10.190

3.  Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.

Authors:  Tatsuo Kawai; Takehiko Takayanagi; Steven J Forrester; Kyle J Preston; Takashi Obama; Toshiyuki Tsuji; Tomonori Kobayashi; Michael J Boyer; Hannah A Cooper; Hang Fai Kwok; Tomoki Hashimoto; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Hypertension       Date:  2017-09-25       Impact factor: 10.190

Review 4.  Aortic Aneurysms.

Authors:  Hong Lu; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06       Impact factor: 8.311

Review 5.  Updates of Recent Aortic Aneurysm Research.

Authors:  Frank M Davis; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 7.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

8.  Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.

Authors:  Haojun Xuan; Baohui Xu; Wei Wang; Hiroki Tanaka; Naoki Fujimura; Masaaki Miyata; Sara A Michie; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2017-04-20       Impact factor: 4.268

Review 9.  Reactive oxygen species: key regulators in vascular health and diseases.

Authors:  Qishan Chen; Qiwen Wang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

10.  Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms.

Authors:  Yunxia Wang; Cong Chen; Qinyu Wang; Yini Cao; Lu Xu; Rong Qi
Journal:  Br J Pharmacol       Date:  2018-12-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.